Macclesfield, United Kingdom

Alan John Foubister

This inventor holds 1 USPTO granted patent. Top assignee: Zeneca Limited. Active years: 2002.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Alan John Foubister. Retrieved from https://idiyas.com/inventor/alan-john-foubister

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2002

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Alan John Foubister: Innovator in Heterocyclic Compounds

Introduction

Alan John Foubister is a notable inventor based in Macclesfield, GB. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that can aid in lowering cholesterol levels.

Latest Patents

Foubister holds a patent for "Heterocyclic compounds useful as oxido-squalene cyclase inhibitors." This invention focuses on heterocyclic derivatives that inhibit oxido-squalene cyclase, which is crucial in cholesterol biosynthesis. The patent outlines processes for preparing these compounds and their use in pharmaceutical compositions. The derivatives are particularly relevant for treating medical conditions such as hypercholesterolemia and atherosclerosis.

Career Highlights

Foubister has worked with Zeneca Limited, a company known for its innovative approaches in the pharmaceutical industry. His work has contributed to advancements in treatments aimed at managing cholesterol levels in the blood.

Collaborations

Throughout his career, Foubister has collaborated with notable colleagues, including George R Brown and Nicholas John Newcombe. These partnerships have likely enhanced the research and development of his patented compounds.

Conclusion

Alan John Foubister's work in developing heterocyclic compounds represents a significant advancement in the fight against cholesterol-related health issues. His contributions continue to impact the pharmaceutical field positively.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…